Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products

🇰🇷 Laotian Times (KR) —

AI Summary

Alteogen Inc. has signed an option and license agreement with Novartis granting Novartis rights to develop and commercialize subcutaneous formulations using Alteogen’s Hybrozyme™ platform. This marks Alteogen’s fourth licensing agreement in 2026, emphasizing its platform expansion.

Novartis obtains rights to develop and commercialize subcutaneous formulations for multiple products utilizing ALT-B4 Alteogen’s fourth licensing agreement signed this year further accelerating the expansion of the Hybrozyme™ platform DAEJEON, South Korea, Sept. 2, 2026 /PRNewswire/ — Alteogen Inc. (KOSDAQ: 196170), a leading biopharmaceutical company specializing in platform technologies, announced today that it has entered into […]

Markets Deals Health Alteogen Novartis licensing agreement Hybrozyme biopharmaceutical subcutaneous products platform technology

Read original source →